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Abstract: The appearance, over a decade ago, of continuous glucose monitoring (CGM) devices has
triggered a patient-centred revolution in the control and management of diabetes mellitus and other
metabolic conditions, improving the patient’s glycaemic control and quality of life. Such devices,
the use of which remains typically restricted to high-income countries on account of their elevated
costs, at present show very limited implantation in resource-constrained settings, where many other
urgent health priorities beyond diabetes prevention and management still need to be resolved. In this
commentary, we argue that such devices could have an additional utility in low-income settings,
whereby they could be selectively used among severely ill children admitted to hospital for closer
monitoring of paediatric hypoglycaemia, a life-threatening condition often complicating severe cases
of malaria, malnutrition, and other common paediatric conditions.
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1. Introduction
The advent of technological developments has allowed, in recent years, a significant improvement
in the management of diabetes mellitus (DM) globally, including the development of a plethora
of point-of-care (PoC) and point-of-need technologies. These have, on account of their simplicity,
immediateness of results, precision, and reliability, simplified and democratized the screening,
management, and follow-up of this condition. Examples of these devices include improved blood
glucose meters, glycated haemoglobin A1c PoC tests, blood betahydroxybutyrate analysers, full lipid
panel biochemical PoC, and semi-quantitative urine dipstick or fully automated urinalysis PoC
methods [1]. Continuous glucose monitoring (CGM) devices, and the possibility of linking them
to new “wearable” insulin delivery systems or pumps, have revolutionized the management of DM,
allowing for more patient-centred and intensive monitoring of glycaemia values and trends, improving
the knowledge-based capacity to adjust therapeutic dosing.
The CGM approach presents some additional interesting advantages. Current recommendations
for assessing glycaemic control involve the periodic monitoring of glycated haemoglobin (HbA1c),
a method reflecting average plasma glucose over the preceding 8–12 weeks [2]. This is a relatively
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simple laboratory-based method, not requiring any special preparation such as fasting. This method
can be performed at any time of the day. However, HbA1c levels only reflect average glycaemia
concentrations, and cannot characterize day-to-day glycaemic fluctuations or particular excursions
(hypoglycaemia, postprandial hyperglycaemia) that may be at the root of acute events or potential
diabetes-associated complications. CGM devices could address, at least partially, some of the limitations
related to self-monitoring of blood glucose and HbA1c testing, outperforming HbA1c as the sole marker
of glycaemic control and thus also facilitating a real-time evaluation of time spent in the target glucose
range [3]. CGM devices have also partially removed the nuisance of continuous blood-pricking,
providing an uninterrupted and close evaluation of interstitial glucose levels, an acceptable proxy
measurement of real glycaemia [4]. Although their use requires the initial insertion of the sensor
under the skin (which is a relatively simple and automatized procedure using the commercial products
available), the devices can provide continuous and real-time readings for up to a week at a time [3,5].
For all of the aforementioned reasons, the uptake of CGM devices in high-income countries
(HICs) is swiftly increasing, with good acceptability and favourable evaluation from end-users [6,7],
and an overall impression that they empower patients and contribute to a better control of the disease.
The high costs associated with using these devices, particularly if having to privately purchase them,
remain a major barrier to wider use.
2. Glycaemia-Associated Problems in Low-Income Countries
2.1. The Problem of Diabetes Mellitus in Resource-Constrained Settings
The escalating global diabetes epidemic that the 21st century is witnessing is one of the major
tribulations of the global health community. The burden and impact of diabetes mellitus (DM)
in resource-constrained settings is far from being adequately characterized, but recent estimates
suggest that DM has increased faster there than in more industrialized settings, both in terms of
its general prevalence and also in the overall number of adults affected [8], possibly as a result of
the inadequacies and shortfalls of current prevention and control programs. Indeed, the number
of adults living with DM, which has quadrupled in the last quarter of a century globally, appears
to be now rapidly increasing not only in rich settings, where this disease has traditionally found a
niche, but also among those populations in low and middle-income countries (LMICs) progressing
through a demographic transition, and is directly linked with other risk factors associated with poor
health outcomes. One of the major caveats of the new technological revolution in regards to DM
care is, despite its enormous potential, the slow penetration of new PoC devices and diagnostic and
therapeutic aids in LMICs, possibly in relation to their current prohibitive costs. In rural areas of
low-income countries, and particularly in Sub-Saharan Africa, where qualified human resources in the
health system are scarce and laboratory infrastructures and diagnostic tool availability are very limited,
challenges for DM prevention and control become dramatically blatant, as standard management of
diabetes is poor or non-existent. Thus, in these settings, and recognizing that many other pressing
health priorities and access inequities still need to be resolved, urgent action is required to increase the
availability of DM therapeutics and diagnostic aids, and also to expose the huge uncovered burden
of metabolic disease, allowing more feasible and targeted policy recommendations which can be
implemented to impact the burden and prognosis of DM.
2.2. The Burden, Impact, and Risk-Factors for Hypoglycaemia in Low-Income Settings
In LMICs, hypoglycaemia appears as a significant albeit poorly recognized public health problem.
The definition of hypoglycaemia implies the detection in an individual of an abnormally low level of
blood sugar. Hypoglycaemia thresholds in children, as defined by the World Health Organization,
depend on nutritional status, and usually entail a glycaemia level <2.5 mmol/L (45 mg/dL) in an
adequately-nourished child, or <3 mmol/L (54 mg/dL) in a severely malnourished child [9]. Current
screening of hypoglycaemia at the bedside of the patient is generally conducted by means of simple and
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relatively inexpensive bedside glucometers, which provide an immediate and actionable measurement
at any given point of interest. Their generalized use, including in low-income settings, has allowed
for the characterization of hypoglycaemia as a major and increasingly acknowledged risk factor for
morbidity and mortality, particularly in developing settings. As a paradigmatic example, the prevalence
of hypoglycaemia among paediatric admissions in Sub-Saharan Africa has been estimated to range
between 1.8% and 7.3% [10,11]. The consequences of severe or prolonged hypoglycaemia are dreaded,
as this condition can result in significant morbidity, for example recurrent seizures, neurological
deficits, or even mental retardation [12,13]. Indeed, the appearance of hypoglycaemia in the course
of any severe condition is often considered a proxy of the severity of illness, and a harbinger of an
adverse outcome, although it is still not well understood how proactive preventive strategies for
hypoglycaemia could impact the risk of death. Hypoglycaemia may affect both children and adults
(including pregnant women) [14–16], with newborns and malnourished children being the most
vulnerable groups [17–19]. A study describing the prevalence and incidence of hypoglycaemia for
all-cause admissions among a large cohort of nearly 50,000 children admitted to a rural Mozambican
hospital during a 13-year long period reported an overall high prevalence of hypoglycaemia (3.2%),
rising to 8.8% when considering the neonatal period alone. Particularly worrying was the excessive
and unacceptable risk of death associated to hypoglycaemia, considering this complication is easily and
readily treatable, with nearly one of every five patients affected dying. Importantly, such results are
likely an underestimation of the true burden of impact, as glycaemia in this cohort was only detected
through a single screening upon admission, and not throughout the rest of the hospitalization [20,21].
Unfortunately, this a common strategy in resource-constrained settings where one aims to make best
use of the few tests available.
In resource-constrained settings, hypoglycaemia typically appears in the context of specific
conditions such as malaria, diarrhoea, or malnutrition, or as a result of other life-threatening conditions
(including meningitis and sepsis) or situations (i.e., the neonatal period) often associated with
glycaemia homeostasis disturbances [11,22–27].
In the neonatal period, hypoglycaemia is a significant cause of disease and death, and lack of
detection or improper management can lead to severe neurological sequelae or lethal outcomes [17,18].
As newborns rely on their mothers for feeding, any common neonatal health problem, including
prematurity, birth asphyxia, or infection, may hinder the newborn’s capacity to feed, thus impairing
proper nutrition. Newborns are therefore highly vulnerable to blood glucose homeostasis impairments,
although the true burden of hypoglycaemia among newborns from developing settings remains
enigmatic as routine control of glycaemia is seldom assessed.
Malaria is a well-known cause of hypoglycaemia. The underlying mechanisms for it are
multifactorial, including, among others, an excessive consumption of glucose by the Plasmodium
parasite, the hyperinsulinaemic adverse effect resulting from the use of certain antimalarials (for
instance quinine, typically in pregnancy), and the insufficient or inadequate supplementation/oral
intake in cases of severe disease, particularly in cerebral malaria cases [24,27–29]. Indeed,
hypoglycaemia is a defining feature of severe malaria [9], often accompanying other complications
such as acidaemia/hyperlactataemia [30]. In severe malaria patients, it is also a treatable cause of
coma and convulsions [9]. The prevalence of malaria-associated hypoglycaemia seems to vary in
different parts of the world, but can occur in up to a quarter of hospitalized malaria patients [31]. The
prognostic implications of hypoglycaemia as part of severe malaria can be easily understood when
comparing the mortality risk in patients with (associated case fatality rates (CFR) of 24–61.5%) or
without (CFR 8–13.4%) this complication [32–34].
Another condition typically associated to an increased risk of hypoglycaemia is severe
malnutrition. It has been estimated that malnutrition significantly contributes to at least one third of
all global child deaths and the presence of hypoglycaemia is potentially a major contributing factor to
such a poor prognosis [19]. In these patients, several factors may compromise glucose homeostasis,
such as for instance a shortage in the exogenous nutritional intake, the reduced absorption of sugars
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resulting from intestinal villous atrophy, or a generalized augment in oxidative stress. The rigorous
application of the WHO management of malnutrition guidelines significantly improves the prognosis
in these patients, likely in relation to the fact that these guidelines take into special consideration the
prevention and early treatment of sepsis and hypoglycaemia [35].
2.3. Continuous Glucose Monitoring for Hypoglycaemia Detection in Severely Ill Hospitalized Children in
Low-Income Settings
Very little research has been conducted in LMICs specifically exploring the utilization of
continuous glucose monitoring for the screening and monitoring of hypoglycaemia. This is not a
surprise as bedside glucometers remain much more cost-effective to screen for this complication,
and current costs do not support the routine use of CGM in these settings. However, these devices
have been used for research purposes, with the aim of better characterizing the burden of recurrent
hypoglycaemia among severely ill children during hospitalization. A study among 74 malaria
paediatric patients in Southern Mozambique concluded that CGM was a reliable and clinically accurate
tool to evaluate blood glucose levels in paediatric malaria patients, and that hypoglycaemia episodes
beyond admission in such patients appeared to occur significantly more commonly than previously
considered. In this study, the insertion of a CGM device during the initial and most critical days
of admission allowed for enhanced detection of low glycaemia episodes, in addition to a more
robust and continuous characterization of the dynamics and evolution of blood glucose. The CGM
instrument could thus be selectively utilized to better monitor those severely ill patients at higher risk
of developing life-threatening hypoglycaemia episodes, allowing for more precise targeting of glucose
supplementation and closer observation to improve prognosis during the hospital stay. Studies among
other vulnerable populations in low-income settings are now underway, with the aim of assessing
the utility of CGM systems among sick neonates and severely malnourished children, two high-risk
populations for developing hypoglycaemic episodes.
It will be important to determine whether the particularities of these two populations in
terms of fat tissue body composition will allow for the correct functioning and accuracy of the
sensors, and therefore reliable monitoring of the outcome. Additionally, the use of CGM in LMIC
faces other limitations, including the potential interactions between CGM and certain drugs such
as acetaminophen [36], the fact that CGM transmitters can be damaged during computerized
tomography/Magnetic Resonance Imaging studies, and the challenges of using such devices in
situations of hemodynamic instability.
3. Conclusions
The uptake and implementation of CGM devices has significantly altered the management and
control of DM wherever it has been implemented, and up-scale of their use for this purpose will likely
be beneficial and cost-effective globally, although it is foreseeable that their use in LMICs in the short
term will remain anecdotal. In these settings, however, additional public health benefits could be
expected if such devices were to be selectively utilized for the monitoring, during hospitalization,
of severely ill patients at high risk of developing hypoglycaemia, a common but insufficiently
recognized complication of many frequent paediatric conditions which is associated with an excessive
and unacceptable risk of death. High quality research evaluating the specific cost-effectiveness of these
continuous monitoring devices for altering the prognosis of this life-threatening complication is needed,
particularly in relation to their current prohibitive costs, which make them unaffordable for wider
general use in settings with many other pressing needs. International consensus recommendations on
the use of CGM [3], currently very much focused on their use for DM control, should widen their scope
so as to also consider in the future their potential contributing role to the monitoring of hypoglycaemia
among severely ill children from LMICs, as this is a common complication that can significantly alter
the prognosis of many common conditions in these settings.
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